The reiteration of an Outperform rating and a maintained price target of $125 by a reputable analyst firm like RBC Capital could positively influence investor sentiment towards Moderna. This endorsement reaffirms confidence in Moderna's potential, likely leading to a short-term positive impact on its stock price.